DEA Delays Marijuana Rescheduling Amid Constitutional and Treaty Challenges

Administrative Procedure Stalls on Legal Questions

The DEA has postponed finalizing its Notice of Proposed Rulemaking (NPRM) for marijuana rescheduling pending resolution of constitutional and treaty-law challenges filed in federal court. The agency published the NPRM in May 2024, triggering a public-comment period that drew over 43,000 submissions. Administrative Law Judge hearings concluded in December 2025. The agency hasn't issued a final rule.

The delay stems from ongoing litigation challenging the agency's authority to reschedule marijuana under 21 U.S.C. § 811 without violating the Single Convention on Narcotic Drugs of 1961, according to the DEA's May 26 statement. The United States is a signatory to that treaty, which classifies cannabis under Schedule I alongside heroin and cocaine.

The DEA didn't provide a revised timeline for completing the rulemaking. Industry observers had expected a final rule by mid-2026.

Constitutional Challenges Target Delegation Authority

At least three federal lawsuits now question whether the Controlled Substances Act unconstitutionally delegates legislative authority to the executive branch. Plaintiffs include a coalition of state attorneys general and a group of Schedule I research license holders who argue that rescheduling marijuana without congressional action violates the nondelegation doctrine.

Cases are pending in the U.S. District Court for the District of Columbia and the Fifth Circuit. No court has issued a preliminary injunction, but the DEA's delay suggests the agency is awaiting judicial clarity before proceeding.

Critics contend that the CSA's eight-factor test for scheduling—codified at 21 U.S.C. § 811(c)—grants excessive discretion to executive agencies, and the constitutional argument centers on whether Congress provided an "intelligible principle" when it authorized the Attorney General to add, remove, or reschedule substances based on HHS recommendations.

Treaty Conflicts Complicate International Compliance

The Single Convention on Narcotic Drugs requires signatory nations to maintain cannabis in Schedule I unless they formally denounce the treaty or seek an amendment through the United Nations Commission on Narcotic Drugs. The United States has done neither. Legal scholars argue that rescheduling marijuana to Schedule III without treaty modification could place the U.S. in breach of its international obligations.

The DEA's May 26 statement acknowledged "ongoing interagency consultations" with the State Department and the Office of the Legal Adviser regarding treaty compliance. It didn't specify whether the agency would seek a formal treaty reservation or rely on a legal interpretation that domestic rescheduling doesn't trigger treaty violations.

Canada and Uruguay, both Single Convention signatories, legalized recreational marijuana by invoking treaty reservations or reinterpreting their obligations. The U.S. hasn't signaled which path it'll follow.

Impact on 280E Tax Relief and Banking Access

Rescheduling marijuana to Schedule III would allow state-licensed cannabis businesses to deduct ordinary business expenses under 26 U.S.C. § 280E, a tax provision that currently prohibits deductions for trafficking in Schedule I or II substances. Industry groups estimate that 280E costs cannabis operators 70% effective tax rates, draining $1.8 billion annually from the sector.

The delay extends that tax burden indefinitely. Multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries had forecast 280E relief in their 2026 earnings guidance. Those projections now face revision.

Banking restrictions under the Bank Secrecy Act or the Controlled Substances Act would remain unresolved by rescheduling—both treat marijuana commerce as money laundering regardless of schedule. The SAFER Banking Act, which would provide explicit safe harbor for financial institutions serving state-legal cannabis businesses, remains stalled in the House of Representatives.

Federal Court Scrutiny of Administrative Record

Federal judges reviewing the rescheduling litigation have requested the full administrative record underlying the HHS recommendation, including clinical trial data, abuse-potential assessments, and international scheduling comparisons. The DEA submitted a 5,200-page record in March 2026. Plaintiffs have moved to compel production of additional documents they allege the agency withheld.

The administrative record includes FDA analyses concluding that marijuana has "currently accepted medical use" for certain conditions, a finding that disqualifies Schedule I classification under the CSA's five-part test. Opponents argue that the FDA relied on state-level observational data rather than double-blind randomized controlled trials, the gold standard for federal drug approval.

If a court vacates the HHS recommendation on procedural grounds, the DEA would be required to restart the rescheduling process from the beginning. That outcome could delay any schedule change by years.

What Comes Next

The DEA's next move depends on rulings in the pending constitutional and treaty-compliance cases, none of which have scheduled oral arguments. The agency has three options: finalize the rule and defend it in court, withdraw the NPRM and await congressional action, or issue an interim final rule with a delayed effective date.

Congressional alternatives include the Cannabis Administration and Opportunity Act, which would deschedule marijuana entirely, and the States Reform Act, which would reschedule to Schedule III by statute. Neither bill has advanced out of committee in the current session.

For background on the rulemaking timeline and HHS recommendation, see the CannIntel topic hub on DEA rescheduling. The administrative process has now stretched 34 months since the initial HHS letter. No final rule in sight. Watch for any district court ruling on the nondelegation challenges, expected by late summer 2026.